Hmdb loader

HMDBP00845 (Ceramide glucosyltransferase) Metabolite Associations

Displaying metabolite protein links 101 - 108 of 108 in total
HMDB ID Name CAS NumberStructureFormula Average Mass
Monoisotopic Mass 		References
HMDB00123153-O-Sulfogalactosylceramide (d18:1/20:0)265096-81-9ThumbC44H85NO11S836.211
835.584333257		Not Available
HMDB00123163-O-Sulfogalactosylceramide (d18:1/22:0)265096-83-1ThumbC46H89NO11S864.264
863.615633385		Not Available
HMDB00123173-O-Sulfogalactosylceramide (d18:1/18:1(9Z))ThumbC42H79NO11S806.142
805.537383065		Not Available
HMDB00123183-O-Sulfogalactosylceramide (d18:1/24:1(15Z))151057-28-2ThumbC48H91NO11S890.301
889.631283449		Not Available
HMDB00123193-O-Sulfogalactosylceramide (d18:1/26:1(17Z))928346-40-1ThumbC50H95NO11S918.354
917.662583577		Not Available
HMDB0012320Galactosylceramide (d18:1/12:0)111956-48-0ThumbC36H69NO8643.935
643.502318189		Not Available
HMDB0012321Galactosylceramide (d18:1/14:0)148347-41-5ThumbC38H73NO8671.9881
671.533618317		Not Available
HMDB0014563Miglustat72599-27-0ThumbC10H21NO4219.278
219.147058165
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60. [PubMed:12803929 ]
  3. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9. [PubMed:16247743 ]
  4. Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21. [PubMed:17603755 ]
  5. Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314. [PubMed:17624027 ]
  6. Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008 Apr;4(2):425-31. [PubMed:18728838 ]
  7. Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18. [PubMed:19956552 ]
  8. Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82. [PubMed:18221193 ]
  9. McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6. [PubMed:14609352 ]
  10. Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19. [PubMed:16627252 ]
Displaying metabolite protein links 101 - 108 of 108 in total